(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Chicago reports first rabies-positive dog in 61 years. What we know. - 2How did life begin on Earth? New experiments support 'RNA world' hypothesis
- 3Moon-bound Artemis II astronauts enjoy a relaxed day in space
- 4Putin says Russian forces will seize capital of Zaporizhzhya
- 5Relive NASA's historic Artemis 2 launch to the moon in these stunning photos
- International issues on the agenda as Frances's Macron visits China
- Aluminum salts emerge as likely target as health officials scrutinize childhood vaccines
- Instructions to Adjust Work, Life, and Seeking after a Web based Advertising Degree
- Sean 'Diddy' Combs faces new sexual assault allegations, currently under investigation by Los Angeles Sheriff's Department
- This country music star spent years hiding his sexuality. Coming out — and beating addiction — has made his soul feel '20 pounds lighter.'
- April full moon 2026 dazzles as 'Pink Moon' lights up skies worldwide (photos)
- Vote In favor of Your Favored Shades
- Collins Foods to offload 20 Taco Bell outlets in Australia
- Roche breast cancer pill cuts risk of disease recurrence by 30% in trial
